Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. - Wikidata - wikimedia - TriplyDB

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

http://www.wikidata.org/entity/Q36309974

about

Current Status of Hepatic Arterial Infusion Chemotherapy Role of supportive care for terminal stage hepatocellular carcinoma Challenges of advanced hepatocellular carcinoma Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort.Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread Screening for hepatocellular carcinoma by Egyptian physicians.Recurrence of Hepatocellular Carcinoma With Epithelial-Mesenchymal Transition After Spontaneous Regression: A Case Report.Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors.Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma.Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.Autophagy: A novel therapeutic target for hepatocarcinoma (Review).Treatment of hepatocellular carcinoma: present and future.Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?Staging systems of hepatocellular carcinoma: a review of literature.Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure Prognosis of untreated hepatocellular carcinoma.Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review.Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 - active palliative treatment improved overall survival.Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B).Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma.The 4th Asia-Pacific Primary Liver Cancer Expert Meeting Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma.Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease.

P2860

Q26775437-E9CD940B-5486-4E35-80AC-94AF406D8AF9 Q26822263-9ECD3B01-15B9-4415-9C8A-36D0CE67C448 Q28076867-86E8F683-3A28-4057-82F4-93FEEB578580 Q33416414-E47B5A2C-1D97-4DB6-8B27-3F393910E31C Q35114970-DA5E1676-F27A-445D-B8C0-50914614ECF7 Q35626761-B89ACBA3-F732-48AB-AC3A-CDD912FD32BD Q35951070-97680E09-B93F-426C-B93E-FD2282F845A8 Q36059063-1351E653-FD92-40DD-AA73-AB45D700AF70 Q36196567-28311677-6DFB-476D-BA82-B985E288D853 Q37031741-0A458D39-01F0-4E4D-A2FE-FD0CD8192B0B Q37158120-D9ADEBE5-B350-4121-A479-8572B54BF956 Q37242795-02EFF007-41A4-4E0D-8614-24FD002D8B70 Q37720015-04881277-E9A1-4974-9D55-4FD17FCB0E96 Q38096477-67812BAF-D03F-4B50-B0A6-F8444208607B Q38162294-49931A6D-8ECA-40D9-B96B-E990199C5A81 Q38207014-0951A4E3-72BF-41E4-8C5E-680336886597 Q38213650-1FBC7F90-934E-47B3-9FD4-BD1A234B8233 Q38635603-BCCB2A4C-CA59-4B15-84B9-E9C140A10B13 Q38811331-406FBCC6-B3D5-4E57-AB6D-833DEC0D5B71 Q38971537-9C409AD9-7B49-4C8D-9082-2A0F323E5027 Q39126855-C66DA3C3-7FC9-4F21-BC9B-910FDBFCDCB7 Q40099351-92F3691D-72A6-445F-80F5-6930B900736B Q40329199-9DC8096C-7FEA-405A-8AF3-0BF56F765831 Q40477968-130B1975-8A43-4B86-B3CB-47DE23BE50C4 Q40597591-84D2AFD3-FD9F-4522-B0B6-AD57E070971D Q44525314-F6CC09BD-900F-4B2F-ADA0-EDE580CBB6C4 Q46264494-F6AF2F9F-55C0-4945-AD97-EE03A4C31041 Q47121517-D8B235DC-3F22-456E-B261-5BBC99989AA0 Q48411584-D9C4B286-A9B5-4A1E-919A-8B0A40B96FA1 Q49796251-5CC7788B-6BAE-447F-BF73-DEA13966313B Q52604161-507D2DA6-A350-455F-A33E-DF2880F6CBF5 Q54965293-D6056ED2-E73A-4F37-9EED-21ACA4B2E3FF

P2860

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

http://www.wikidata.org/entity/Q36309974

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

@ast

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

@en

type

label

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

@ast

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

@en

prefLabel

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

@ast

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

@en

P1433

Q36309974-8D2C4CFC-998A-4192-B12A-7FBC263330EE

P1476

Q36309974-415A2501-0EE4-4250-9E14-B89CB8BB9B46

P2093

Q36309974-03B80648-5162-4376-A826-E531CEE1EEAB

Q36309974-1CAE7485-A91B-4CDF-8976-918DABE39436

Q36309974-1E745BEA-D1E8-4487-A15B-7011EB4A97DA

Q36309974-335FA4F5-462B-4343-B622-28D34919FAA9

Q36309974-42046945-A9F1-4044-A296-6A0858E4DA90

Q36309974-4A6D2F43-29AC-47F6-AECA-39E237A91988

Q36309974-58192AD0-C51F-4B28-80E5-2EFB1B3736CB

Q36309974-6E54B382-D0D6-4679-B45F-3555E6D664A7

Q36309974-6F794F7C-5539-47C7-BE11-F15B345E2B93

Q36309974-B7D860A1-242B-474D-B762-C02B864417D7

P2860

Q36309974-12B2BCCF-00D2-4FFF-912B-104B11CD20A8

Q36309974-1DABDEFC-25CD-42BE-B032-9FEF5B248561

Q36309974-2763FEAC-4B4B-468C-99C4-E135205FA080

Q36309974-32CECDC6-B765-4130-86E2-EF7820469F96

Q36309974-33E143D0-DA46-47B0-939F-FF380DCBEB56

Q36309974-5A08C97A-CAAB-4ED5-A0BF-AAD4E0F5CBCE

Q36309974-60FD2FC0-4A72-4BC8-B9E6-C2F2E894DF9A

Q36309974-7D4503B7-7082-4A21-BA7D-0FEBE444CA14

Q36309974-8380F05A-542E-4053-AF9A-DD2B1028864A

Q36309974-93AC34F5-B8D0-4D60-A58D-15499A78A2C5

P304

Q36309974-6BA920D5-6980-4364-8782-836A89EABF13

P31

Q36309974-7CC2F8F8-89B5-4D8F-9B49-CB6C29F0B10D

P356

Q36309974-AED509BA-F3B1-4C35-90EA-3F5D120F036A

P433

Q36309974-5E9B9934-4CBF-4DE3-BFEC-3C6C323CD3DF

P478

Q36309974-118D684E-3846-4D10-A12B-7BCE4D4A8CE3

P577

Q36309974-8910742A-5869-4577-81D0-A6FE4CC4A5BB

P5875

Q36309974-182439D1-20FB-49EA-BF95-6F2B39EB6A77

P698

Q36309974-D5673F98-9E37-45EF-B853-21CC45987BED

P932

Q36309974-0EF6240F-2F1A-4E14-8935-359B0F0E83DF

P356

P1433

World journal of hepatology

P1476

Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.

@en

P2093

Antonio Craxì

http://www.w3.org/2001/XMLSchema#string

Calogero Cammà

http://www.w3.org/2001/XMLSchema#string

Chiara Genco

http://www.w3.org/2001/XMLSchema#string

Giuseppe Brancatelli

http://www.w3.org/2001/XMLSchema#string

Giuseppe Cabibbo

http://www.w3.org/2001/XMLSchema#string

Marcello Maida

http://www.w3.org/2001/XMLSchema#string

Marco Peralta

http://www.w3.org/2001/XMLSchema#string

Michela Antonucci

http://www.w3.org/2001/XMLSchema#string

Pietro Parisi

http://www.w3.org/2001/XMLSchema#string

Vito Di Marco

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hepatocellular carcinoma: An update

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma

Management of hepatocellular carcinoma

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Prognosis of hepatocellular carcinoma: the BCLC staging classification

Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment.

Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib.

P304

256-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4254/WJH.V4.I9.256

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232237132

http://www.w3.org/2001/XMLSchema#string

P698

23060970

http://www.w3.org/2001/XMLSchema#string

P932

3468702

http://www.w3.org/2001/XMLSchema#string